Novartis Buys Avidity Biosciences in $12 Billion Deal to Expand Rare Disease Portfolio
Think of this deal like a sports team signing a star rookie—Novartis is paying big money to bring fresh talent (Avidity Biosciences) onto its team, hoping to win more games in the future. For investors,…